RAEB
MCID: MYL074
MIFTS: 38

Myelodysplastic Syndrome with Excess Blasts (RAEB)

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Myelodysplastic Syndrome with Excess Blasts

MalaCards integrated aliases for Myelodysplastic Syndrome with Excess Blasts:

Name: Myelodysplastic Syndrome with Excess Blasts 52
Refractory Anemia with Excess Blasts 52 58 17
Raeb 52 58

Characteristics:

Orphanet epidemiological data:

58
refractory anemia with excess blasts
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D000754
ICD10 via Orphanet 33 D46.2
UMLS via Orphanet 72 C0002894
Orphanet 58 ORPHA86839

Summaries for Myelodysplastic Syndrome with Excess Blasts

NIH Rare Diseases : 52 Myelodysplastic syndrome with excess blasts is a rare type of myelodysplastic syndrome (MDS). In this type of MDS, the number of very early forms of blood cells (blasts) are increased in the bone marrow and/or blood. There is also a low numbers of at least one type of blood cell. The early forms of cell types in the bone marrow (red blood cells , white blood cells , or platelets ) may or may not look abnormal (dysplasia) under the microscope. Signs and symptoms may include a very hard to treat and persistent anemia (refractory anemia), frequent infections (due to low numbers of neutrophils), easy bruising and bleeding (due to low number or abnormal platelets). MDS with excess blasts is one of the MDS most likely to turn into acute myeloid leukemia (AML) . It is classified into 2 types, based on how many of the cells in the bone marrow or blood are blasts: MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood; this type has a higher risk to become AML. Some cases of MDS are linked to known risk factors (such as smoking, chemotherapy , having a genetic syndrome that increases the chance of developing MDS and other). These factors lead to changes in the DNA in bone marrow cells may cause MDS to develop, but most often, the cause is unknown. Treatment may include blood transfusions, supportive care, chemotherapy, radiotherapy and bone marrow transplant . [ 14773]

MalaCards based summary : Myelodysplastic Syndrome with Excess Blasts, also known as refractory anemia with excess blasts, is related to aplastic anemia and refractory anemia with excess blasts type 2. An important gene associated with Myelodysplastic Syndrome with Excess Blasts is TET2 (Tet Methylcytosine Dioxygenase 2). The drugs Sargramostim and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are fatigue and anemia of inadequate production

Related Diseases for Myelodysplastic Syndrome with Excess Blasts

Diseases related to Myelodysplastic Syndrome with Excess Blasts via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 29.2 TET2 LTA
2 refractory anemia with excess blasts type 2 12.9
3 refractory anemia with excess blasts type 1 12.8
4 refractory anemia with excess blasts in transformation 11.7
5 pancytopenia 10.5
6 myelodysplastic syndrome 10.5
7 deficiency anemia 10.4
8 lymphocytic leukemia 10.2
9 refractory cytopenia with multilineage dysplasia 10.2
10 erythroleukemia, familial 10.2
11 leukemia, acute myeloid 10.2
12 refractory anemia 10.2
13 acute promyelocytic leukemia 10.2
14 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
15 leukemia 10.2
16 acute myeloblastic leukemia without maturation 10.2
17 mucositis 10.1
18 48,xyyy 10.1
19 chromosomal triplication 10.1
20 monosomy 22 10.1
21 familial mediterranean fever 10.1
22 severe cutaneous adverse reaction 10.1
23 graft-versus-host disease 10.1
24 leukemia, acute lymphoblastic 3 10.1
25 erythema multiforme 10.1
26 patau syndrome 10.1
27 nephrotic syndrome 10.1
28 ecthyma 10.1
29 thrombocytosis 10.1
30 macrocytic anemia 10.1
31 hyperglycemia 10.1
32 amyloidosis 10.1
33 polyarteritis nodosa 10.1
34 acute graft versus host disease 10.1
35 erythema multiforme major 10.1
36 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.1
37 precursor t-cell acute lymphoblastic leukemia 10.1
38 acute leukemia 10.1
39 myeloid leukemia 10.1
40 acute erythroid leukemia 10.1
41 acute leukemia of ambiguous lineage 10.1
42 aregenerative anemia 10.1
43 factor viii deficiency 10.0
44 kaposi sarcoma 10.0
45 chromosome 5q deletion syndrome 10.0
46 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
47 hemophilia a 10.0
48 alpha-thalassemia 10.0
49 hemoglobin h disease 10.0
50 chronic myelomonocytic leukemia 10.0

Graphical network of the top 20 diseases related to Myelodysplastic Syndrome with Excess Blasts:



Diseases related to Myelodysplastic Syndrome with Excess Blasts

Symptoms & Phenotypes for Myelodysplastic Syndrome with Excess Blasts

Human phenotypes related to Myelodysplastic Syndrome with Excess Blasts:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
2 anemia of inadequate production 58 31 hallmark (90%) Very frequent (99-80%) HP:0010972
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 exertional dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002875
5 palpitations 58 31 frequent (33%) Frequent (79-30%) HP:0001962
6 anemic pallor 58 31 frequent (33%) Frequent (79-30%) HP:0001017
7 bone marrow hypocellularity 58 31 occasional (7.5%) Occasional (29-5%) HP:0005528
8 acute myeloid leukemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004808
9 thrombocytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001873
10 leukocytosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001974
11 bone pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002653
12 retinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0000573
13 chronic infection 58 31 occasional (7.5%) Occasional (29-5%) HP:0031035
14 abnormal mean corpuscular volume 58 31 occasional (7.5%) Occasional (29-5%) HP:0025065
15 dysplastic granulopoesis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012136
16 multiple lineage myelodysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012148
17 abnormal albumin level 58 31 occasional (7.5%) Occasional (29-5%) HP:0012116
18 single lineage myelodysplasia 58 31 occasional (7.5%) Occasional (29-5%) HP:0012150
19 pedal edema 31 occasional (7.5%) HP:0010741
20 abnormal bleeding 58 Occasional (29-5%)
21 abnormality of bone marrow cell morphology 58 Occasional (29-5%)
22 edema of the lower limbs 58 Occasional (29-5%)
23 abnormality of circulating protein level 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Myelodysplastic Syndrome with Excess Blasts:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 8.62 LTA TET2

Drugs & Therapeutics for Myelodysplastic Syndrome with Excess Blasts

Drugs for Myelodysplastic Syndrome with Excess Blasts (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
2
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
3
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
4
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 209810-58-2, 11096-26-7
5
Mercaptopurine Approved Phase 3 50-44-2 667490
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
8
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
9
Vidarabine Approved, Investigational Phase 3 24356-66-9 32326 21704
10
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
11
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
12
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
13
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
Thioguanine Approved Phase 3 154-42-7 2723601
17
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
20
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
21
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
22
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
23
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
24
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
25
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
26
Etoposide Approved Phase 3 33419-42-0 36462
27
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
28
Daunorubicin Approved Phase 3 20830-81-3 30323
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
30
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
31
tipifarnib Investigational Phase 2, Phase 3 192185-72-1 159324
32 Antilymphocyte Serum Phase 3
33 Thymoglobulin Phase 3
34 Hematinics Phase 3
35 Epoetin alfa Phase 2, Phase 3 113427-24-0
36 Pharmaceutical Solutions Phase 2, Phase 3
37 Antineoplastic Agents, Immunological Phase 2, Phase 3
38 Alkylating Agents Phase 2, Phase 3
39 Antirheumatic Agents Phase 3
40 Gemtuzumab Phase 3
41 Analgesics Phase 3
42 Keratolytic Agents Phase 3
43 BB 1101 Phase 3
44 Hydrocortisone hemisuccinate Phase 3
45 Hydrocortisone 17-butyrate 21-propionate Phase 3
46 Hydrocortisone-17-butyrate Phase 3
47
asparaginase Phase 3
48 Adjuvants, Immunologic Phase 2, Phase 3
49 Neurotransmitter Agents Phase 3
50 Immunologic Factors Phase 3

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
2 Intravenous Low-Dose Decitabine Versus Supportive Care in Elderly Patients With Primary Myelodysplastic Syndrome (MDS) (>10% Blasts or High-Risk Cytogenetics), Secondary MDS or Chronic Myelomonocytic Leukemia (CMML) Who Are Not Eligible for Intensive Therapy: An EORTC-German MDS Study Group Randomized Phase III Study Unknown status NCT00043134 Phase 3 decitabine
3 A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission Unknown status NCT00003602 Phase 3 cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
4 Autologous Peripheral Blood Stem Cell Transplantation (PSCT) Versus a Second Intensive Consolidation Course After a Common Induction and Consolidation Course in Patients With Bad Prognosis Myelodysplastic Syndromes (MDS) and Acute Myelogenous Leukemia Secondary (SAML) to MDS of More Acute Than 6 Months Duration Unknown status NCT00002926 Phase 3 cytarabine;etoposide;idarubicin
5 REGIME: A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha, With or Without Recombinant Human Granulocyte Colony Stimulating Factor, Versus Best Supportive Care in Patients With Low-risk Myelodysplastic Syndromes (MDS). Unknown status NCT01196715 Phase 3 Darbepoetin alpha;Filgrastim
6 Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
7 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
8 Protocol for the Treatment of Adults Aged </= 60 Years With De Novo Acute Myeloblastic Leukaemia or Secondary AML or RAEB-T (AML 01/99 Trial) Unknown status NCT00209833 Phase 2, Phase 3 Cytarabine;Idarubicin;Etoposide;Fludarabine;G-CSF;Daunorubicine
9 A Randomised Controlled Trial of Prolonged Treatment With Darbepoetin Alpha With or Without Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Versus Best Supportive Care in Patients With Low-Risk Myelodysplastic Syndromes Unknown status NCT00234143 Phase 2, Phase 3 Darbepoetin
10 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
11 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
12 Antithymocyte Globulin (ATG) and Cyclosporine (CSA) to Treat Patients With Myelodysplastic Syndrome (MDS). A Randomized Trial Comparing ATG + CSA With Best Supportive Care Completed NCT00004208 Phase 3 ATG + CSA
13 A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study) Completed NCT00005866 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
14 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
15 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
16 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
17 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
19 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
20 Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 Completed NCT00003436 Phase 3 amsacrine;asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;methotrexate;mitoxantrone hydrochloride;therapeutic hydrocortisone
21 The Unrelated Donor Marrow Transplantation Trial Completed NCT00003187 Phase 2, Phase 3 cyclophosphamide;cyclosporine;cytarabine;methotrexate;methylprednisolone
22 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
23 Risk-stratified Therapy for Primary and Secondary AML and MDS. A Randomized Study by AMLCG in Relation to Cytogenetically Defined Prognostic Factors (1) on the Role of High-dose AraC as Part of Double Induction, (2) on G-CSF Priming, and (3) on High-dose Chemotherapy With Stem Cell Transplantation Completed NCT00266136 Phase 3 Cytarabine;Thioguanine;Daunorubicin;Cyclophosphamide;G-CSF
24 Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome Completed NCT00774280 Phase 3 BuCy vs BuFlu
25 Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02744742 Phase 2, Phase 3 Decitabine;Busulfan (BU);Cyclophosphamide (CY);Granulocyte Colony-Stimulating Factor(G-CSF)
26 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy. Recruiting NCT03839771 Phase 3 AG-120;Placebo for AG-120;AG-221;Placebo for AG-221
27 A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent Recruiting NCT02562443 Phase 3 rigosertib;Any approved or standard-of-care therapy;best supportive care (BSC);best supportive care (BSC)
28 Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3 rigosertib sodium
29 Phase III MultiCenter Randomized Controlled Study to Assess Efficacy and Safety of ON 01910.Na 72-Hr Continuous IV Infusion in MDS Patients With Excess Blasts Relapsing After or Refractory to or Intolerant to Azacitidine or Decitabine Active, not recruiting NCT01241500 Phase 3 ON 01910.Na
30 AML08: A Phase II Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Phase II Study Of Natural Killer Cell Transplantation In Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00703820 Phase 3 Cytarabine;Daunorubicin;Etoposide;Clofarabine
31 A Randomized Multicenter Study of More Intensive Versus Less Intensive Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia (AML) or Transformed Refractory Anemia With Excess Blasts (RAEB-t). Terminated NCT00363025 Phase 3 Idarubicin versus daunorubicin
32 A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes Unknown status NCT00003123 Phase 2 amifostine trihydrate
33 Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study Unknown status NCT00003827 Phase 2 amifostine trihydrate;cytarabine;topotecan hydrochloride
34 Phase Two Multicenter Study Of Arsenic Trioxide In Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
35 A Randomized Study Of The Safety And Efficacy Of Two Dose Schedules Of Gemcituzumab Ozogamicin In Patients With Intermediate-2 Or High-Risk Myelodysplastic Syndromes Unknown status NCT00022321 Phase 2 gemtuzumab ozogamicin
36 An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS) Unknown status NCT00017550 Phase 2
37 Phase 2 Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA 51 VG Adjuvant and Administered With GM-CSF in Low Risk and Intermediate-1 MDS Unknown status NCT00513578 Phase 2
38 Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia Unknown status NCT00003681 Phase 2 amifostine trihydrate
39 Protocol for Treatment of Newly Diagnosed High Risk And Relapsed Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Ethyol and High-Dose Cytarabine + Mitoxantron Followed by Maintenance Phase Using Low-Dose ARA-C, rhGM-CSF, Pentoxifylline, Ciprofloxacin and Decadron Unknown status NCT00003407 Phase 2 amifostine trihydrate;cytarabine;mitoxantrone hydrochloride
40 Phase 2 Study of AR-67 (DB-67) in Myelodysplastic Syndrome(MDS) Unknown status NCT00956787 Phase 2 AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
41 Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy Completed NCT00005942 Phase 1, Phase 2 liposomal daunorubicin citrate;semaxanib
42 A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS) Completed NCT00003675 Phase 2 topotecan hydrochloride
43 A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes Completed NCT00064376 Phase 2 paricalcitol
44 Therapy of Myelodysplastic Syndrome (MDS) With Antithymocyte Globulin (ATG) and TNFR:Fc Completed NCT00005853 Phase 2
45 Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) After T-Lymphocyte Depleted Allogeneic BMT for Myelodysplastic Syndromes Completed NCT00003961 Phase 2
46 Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes Completed NCT00003361 Phase 2 decitabine
47 Phase II Clinical Evaluation of Bryostatin 1 in Patients With Myelodysplastic Syndrome Completed NCT00003171 Phase 2 bryostatin 1
48 A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK222584) (IND #66370, NSC #719335) in Myelodysplastic Syndrome (MDS) Completed NCT00072475 Phase 2 vatalanib
49 A Pilot Study Of FR901228, Or Depsipeptide (NSC #630176) For Adult Patients With Advanced Hematologic Cancers Completed NCT00042822 Phase 2 romidepsin
50 Safety and Efficacy Trial of Bevacizumab: Anti-VEGF Humanized Monoclonal Antibody (NSC 704865) Therapy for Myelodysplastic Syndrome (MDS) Completed NCT00022048 Phase 1, Phase 2

Search NIH Clinical Center for Myelodysplastic Syndrome with Excess Blasts

Genetic Tests for Myelodysplastic Syndrome with Excess Blasts

Anatomical Context for Myelodysplastic Syndrome with Excess Blasts

MalaCards organs/tissues related to Myelodysplastic Syndrome with Excess Blasts:

40
Myeloid, Bone, Bone Marrow, T Cells, Neutrophil, Endothelial, Testes

Publications for Myelodysplastic Syndrome with Excess Blasts

Articles related to Myelodysplastic Syndrome with Excess Blasts:

(show top 50) (show all 425)
# Title Authors PMID Year
1
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)]. 61 52
29070129 2017
2
How I treat myelodysplastic syndromes of childhood. 52
29438960 2018
3
Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. 61
31878809 2019
4
A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation. 61
31309419 2019
5
Pegylated liposomal doxorubicin for myeloid neoplasms. 61
31283544 2019
6
Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome-Refractory anemia with excess blasts type 2. 61
31534742 2019
7
Mixed Phenotype Acute Leukemia that Evolved from Myelodysplastic Syndrome with Excess Blasts. 61
31504737 2019
8
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. 61
31152020 2019
9
Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. 61
31378228 2019
10
Decitabine improves overall survival in myelodysplastic syndromes-RAEB patients aged ≥60 years and has lower toxicities: Comparison with low-dose chemotherapy. 61
31005752 2019
11
Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. 61
30616472 2019
12
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Aplasia After Cladribine/Cytarabine Chemotherapy for Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. 61
30905537 2019
13
[Outcomes and prognostic factors of myelodysplastic syndrome patients with allogeneic hematopoietic stem cell transplantation]. 61
31340621 2019
14
GATA2 mutation in long stand Mycobacterium kansasii infection, myelodysplasia and MonoMAC syndrome: a case-report. 61
31035956 2019
15
[Comparation of Clinical Efficacy between Two Regimens of Preexcitation Chemotherapy for MDS-RAEB Patients]. 61
30998163 2019
16
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. 61
30287621 2019
17
Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia. 61
30368588 2019
18
Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors. 61
30371735 2019
19
Acquired platelet dysfunction and overproduction of platelet cyclic AMP in two patients with myeloid malignancies. 61
31240986 2019
20
Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations. 61
30502853 2018
21
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. 61
30135184 2018
22
Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML. 61
29902706 2018
23
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. 61
29433052 2018
24
[Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing]. 61
29365392 2017
25
TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. 61
28687222 2017
26
Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients. 61
28982058 2017
27
Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. 61
28886412 2017
28
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. 61
28705782 2017
29
[Large vessel vasculitis with myelodysplastic syndrome: A rare association]. 61
28094068 2017
30
Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes. 61
28300669 2017
31
[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen]. 61
28810323 2017
32
p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation. 61
28588781 2017
33
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. 61
27558206 2017
34
Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance. 61
28209754 2017
35
The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50. 61
28013105 2017
36
Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. 61
27663637 2017
37
Myelodysplastic and myeloproliferative disorders of childhood. 61
27913534 2016
38
Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms. 61
27693133 2016
39
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. 61
27443511 2016
40
[Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts]. 61
27801319 2016
41
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. 61
27382099 2016
42
Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in Myelodysplastic Syndrome: Comparison With International Working Group Treatment Response Criteria. 61
27232348 2016
43
Loss of B cells and their precursors is the most constant feature of GATA-2 deficiency in childhood myelodysplastic syndrome. 61
27013649 2016
44
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. 61
26966176 2016
45
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). 61
28092889 2016
46
Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course. 61
27124938 2016
47
Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. 61
27073478 2016
48
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). 61
26855506 2016
49
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 61
26799610 2016
50
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. 61
26133721 2016

Variations for Myelodysplastic Syndrome with Excess Blasts

Expression for Myelodysplastic Syndrome with Excess Blasts

Search GEO for disease gene expression data for Myelodysplastic Syndrome with Excess Blasts.

Pathways for Myelodysplastic Syndrome with Excess Blasts

GO Terms for Myelodysplastic Syndrome with Excess Blasts

Sources for Myelodysplastic Syndrome with Excess Blasts

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....